CorMedix signs deal for Heron's portfolio, backed by Pharmakon loan, targeting $45m–$60m savings
CorMedix has agreed to take over nearly all of Heron Therapeutics' business, with four commercial products generating about $150m a year and cost cuts of up to $60m planned.
CorMedix is betting that scale and cost discipline can make Heron Therapeutics' portfolio more profitable under its ownership. It has signed a definitive agreement to buy nearly all of Heron's assets, and says it can strip $45m to $60m a year from combined costs by the end of 2027.
The assets cover four marketed products: ZYNRELEF, APONVIE, CINVANTI and SUSTOL. CorMedix puts their combined net sales at about $150m over the latest 12-month period. The package also includes a development agreement tied to one new drug application awaiting review at the US Food and Drug Administration. The announcement summary does not identify that product or say when the agency might decide.
The deal is financed in part by a term loan facility from Pharmakon. Neither the price nor the size of the loan has been disclosed in the material available, so the multiple CorMedix is paying for that revenue cannot be calculated.
The agreement was signed on 9 November 2026, and CorMedix published its announcement the next day. Closing needs approval from Heron's stockholders and regulatory clearances. No closing date has been given.
Why it matters
- The $45m–$60m synergy target is large against roughly $150m of sales, so integration execution will drive the deal's economics. The target is the company's own estimate.
- Without a disclosed price or loan size, the deal's valuation and the debt burden on the combined business remain unknown.
- The pending NDA adds a possible pipeline contribution, but its identity and timing are unclear.
- Closing depends on a Heron stockholder vote and regulatory clearances, and no timetable has been announced.
Company's press release (SEC filing): CorMedix Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first
Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review
Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage
Theriva Sells SYN-004 Antibiotic-Enzyme Assets to Biossil Labs for $350,000 Upfront
